Aficamten

Generic Name: Aficamten

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₅O_₂

CAS Number: 2364554-48-1

Unique Ingredient Identifier: B1I77MH6K1

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cytokinetics Announces FDA Acceptance of New Drug

FDA accepted Cytokinetics' NDA for omecamtiv mecarbil, targeting HFrEF, with a PDUFA action date of November 30, 2022. No advisory committee meeting is planned. GALACTIC-HF trial showed omecamtiv mecarbil reduced CV death or heart failure events risk. METEORIC-HF results expected early 2022.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy